Models for women | Models for men | |||||||
---|---|---|---|---|---|---|---|---|
1a | 1b | 2a | 2b | 1a | 1b | 2a | 2b | |
†The models also included age, period, subsite, stage, and histological type/grade (the latter three, when relevant, only in the excess mortality term). The subsite and histological control variables were as defined in table 2. Only effects relative to those with 7–9 years of education are shown. Differences of 0.03–0.05, when compared with results from model 1a, are in bold types, and those larger than 0.05 are in bold, underlined types. *Significant at the 0.05 level. | ||||||||
Stomach | ||||||||
10–12 | 1.00 | 0.99 | 0.99 | 1.00 | 0.95* | 0.94* | 0.94* | 0.94* |
13–16 | 0.96 | 0.95 | 0.94 | 0.95 | 0.94 | 0.92 | 0.92* | 0.91 |
17– | 0.85 | 0.83* | 0.84* | 0.84 | ||||
Colon/rectum | ||||||||
10–12 | 0.87* | 0.86* | 0.86* | 0.87* | 0.95* | 0.93* | 0.94* | 0.93* |
13–16 | 0.89 | 0.87* | 0.87* | 0.90 | 0.87* | 0.84* | 0.85* | 0.86* |
17– | 0.83* | 0.78* | 0.80* | 0.83* | ||||
Pancreas | ||||||||
10–12 | 1.04 | 1.03 | 1.03 | 1.03 | 0.93* | 0.93* | 0.93* | 0.95 |
13–16 | 0.79* | 0.78* | 0.79* | 0.76* | 0.80* | 0.80* | 0.80* | 0.79* |
17– | 1.04 | 1.03 | 1.03 | 1.04 | ||||
Lung | ||||||||
10–12 | 1.04 | 1.03 | 1.03 | 1.03 | 0.93* | 0.92* | 0.93* | 0.93* |
13–16 | 1.15 | 1.14 | 1.14 | 1.13 | 0.87* | 0.86* | 0.87* | 0.96* |
17– | 0.82* | 0.80* | 0.81* | 0.80* | ||||
Breast | ||||||||
10–12 | 0.91* | 0.88* | 0.89* | 0.90* | ||||
13– | 0.76* | 0.73* | 0.75* | 0.76* | ||||
Cervix | ||||||||
10–12 | 1.05 | 1.03 | 1.02 | 1.05 | ||||
13– | 0.91 | 0.89 | 0.87 | 0.96 | ||||
Corpus uteri | ||||||||
10–12 | 0.96 | 0.93 | 0.92 | 0.98 | ||||
13– | 0.89 | 0.84 | 0.84 | 0.92 | ||||
Ovaries | ||||||||
10–12 | 1.00 | 0.99 | 0.99 | 0.99 | ||||
13– | 0.91 | 0.90 | 0.90 | 0.89 | ||||
Prostate | ||||||||
10–12 | 0.90* | 0.86* | 0.89* | 0.91* | ||||
13–16 | 0.96 | 0.89* | 0.90* | 0.94* | ||||
17– | 0.66* | 0.56* | 0.65* | 0.70* | ||||
Bladder | ||||||||
10–12 | 0.83* | 0.81* | 0.83* | 0.81* | 0.89* | 0.85* | 0.88* | 0.87* |
13–16 | 0.70* | 0.66* | 0.72* | 0.69* | 0.79* | 0.74* | 0.76* | 0.79* |
17– | 0.59* | 0.49* | 0.62* | 0.64* | ||||
Malignant melanoma | ||||||||
10–12 | 1.01 | 0.97 | 0.95 | 0.94 | 0.72* | 0.70* | 0.75* | 0.72* |
13–16 | 0.77 | 0.71* | 0.78* | 0.69 | 0.58* | 0.55* | 0.62* | 0.62* |
17– | 0.60* | 0.55* | 0.59* | 0.63* | ||||
Leukaemia | ||||||||
10–12 | 0.94 | 0.93 | 0.93 | 0.92 | 0.90* | 0.89* | 0.90* | 0.89* |
13–16 | 0.84 | 0.84 | 0.84 | 0.84 | 0.81* | 0.80* | 0.81* | 0.82* |
17– | 0.72* | 0.71* | 0.71* | 0.71* | ||||
All sites above | ||||||||
10–12 | 0.96* | 0.94* | 0.94* | 0.95* | 0.92* | 0.90* | 0.91* | 0.91* |
13–16 | 0.86* | 0.84* | 0.85* | 0.86* | 0.88* | 0.85* | 0.86* | 0.87* |
17– | 0.78* | 0.73* | 0.75* | 0.78* |